Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 18:30 |
RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
|
English | 165.6 KB | ||
| 2025-11-13 18:30 |
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 13 NOVEMBRE 2025
|
French | 177.9 KB | ||
| 2025-10-30 23:00 |
Biophytis Reports First-Half 2025 Results and Provides Strategic Update
|
English | 172.7 KB | ||
| 2025-10-13 07:00 |
BIOPHYTIS et un consortium d’investisseurs incluant RONGHUI RENHE Life Technolo…
|
French | 232.5 KB | ||
| 2025-10-13 07:00 |
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology…
|
English | 220.5 KB | ||
| 2025-09-30 07:00 |
Biophytis annonce sa participation à quatre événements clés au cours du 4ème tr…
|
French | 178.1 KB | ||
| 2025-09-30 07:00 |
Biophytis to Participate in Four Key Events in Q4 2025
|
English | 159.5 KB | ||
| 2025-09-15 07:00 |
Biophytis obtient un financement public au Brésil pour l’essai de Phase 2 dans …
|
French | 174.3 KB | ||
| 2025-09-15 07:00 |
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs …
|
English | 137.5 KB | ||
| 2025-09-11 07:00 |
Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO10…
|
French | 124.3 KB | ||
| 2025-09-11 07:00 |
Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and A…
|
English | 125.5 KB | ||
| 2025-09-03 07:00 |
Biophytis obtient l'autorisation de l'EMA pour le lancement de son étude cliniq…
|
French | 104.4 KB | ||
| 2025-09-03 07:00 |
Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in ob…
|
English | 100.1 KB | ||
| 2025-09-01 07:00 |
Biophytis dévoile sa stratégie pour l’essai clinique de phase 2 dans l’obésité …
|
French | 185.3 KB | ||
| 2025-09-01 07:00 |
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Braz…
|
English | 165.0 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
